文献速递乳腺癌

乳腺癌转移与复发潜伏期的突变能力依赖性

Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence.
PubMed 文献 · Cancer Discov · 2026-10-13

该研究分析662对配对及约6000例非配对原发与转移性肿瘤基因组数据,发现转移特异性突变多在播散后获得,APOBEC诱变贡献突出,且集中于10条通路。患者间转移潜伏期差异过半可由播散前后突变获得相对时序解释,支持「突变能力依赖性」转移模型。

要点

  • 转移特异性突变常于播散后获得,APOBEC诱变贡献突出。
  • 95%患者转移特异性突变集中于最少10条通路。
  • 潜伏期差异过半由播散前后突变获得时序解释。

核心结论

  • 乳腺癌转移中功能相关突变多在原发肿瘤播散后积累,并促进转移性生长。
  • 转移潜伏期反映播散肿瘤细胞获得剩余驱动突变所需时间,支持「突变能力依赖性」模型。

研究设计与样本

  • 分析662对配对及约6000例非配对原发与转移性乳腺癌肿瘤的基因组数据。

主要发现

  • 转移特异性突变常在播散后获得,APOBEC介导诱变贡献不成比例。
  • 转移特异性突变集中于高度复发、有别于原发肿瘤且依赖转移部位的通路。
  • 95%患者转移特异性突变位于最少10条通路内。
  • 患者间转移潜伏期差异超过一半可由受累通路中突变获得相对于播散的时序解释。

临床怎么用

  • 解读转移灶新检出突变时需考虑其可能为播散后获得而非原发肿瘤驱动事件。
  • 评估转移风险与潜伏期可关注突变获得时序及APOBEC诱变特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To evaluate the functional relevance of mutations newly detected in breast cancer metastases, we analyzed genomic data from 662 paired and ~6,000 unpaired primary and metastatic tumors. These analyses indicate that metastasis-specific mutations are frequently acquired post-dissemination, with a disproportionate contribution from APOBEC-mediated mutagenesis. Metastasis-specific mutations converged on a set of pathways that were highly recurrent, distinct from those altered in primary tumors, and dependent on metastatic site. 95% of patients harbored metastasis-specific mutations within a minimum set of 10 pathways. Remarkably, more than half the variation in metastatic latency across patients was explained by the relative timing of mutation acquisition within implicated pathways before versus after dissemination. These findings support a "mutability-dependent" model of metastasis in which functionally consequential mutations accumulate after primary tumor dissemination and contribute to metastatic outgrowth, with latency reflecting the time required for DTCs to acquire the remaining driver mutations needed to achieve metastatic competence.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Lawrence-Paul MR, Pan TC, Pant DK, et al. Mutability Dependence of Breast Cancer Metastasis and Latency to Recurrence. Cancer Discov. 2026. PMID: 42867316. doi:10.1158/2159-8290.CD-25-2090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。